Alliance Pharma revenues rise, as pandemic recovery underway
Alliance Pharma reported stronger revenues for the first half of the year, as the healthcare sector continues goes from strength to strength.
The international healthcare group saw revenues grow to £80.9m for the six months ended 30 June 2021 – representing an increase of just under 25 per cent, compared to the same period last year.
The update comes ahead of the Group’s interim results which are expected in September.
The company’s board said it expects its underlying profit before tax for the full year to be in line with market expectations based on its results to date.
An increased demand for prescription medicines resulted in revenues rising by 12 per cent from last year to £24m as the pharmaceutical noted that the delivery of routine treatments returned as the pandemic recovery began.
Alliance chief executive officer, Peter Butterfield, said: “Our Consumer Healthcare business continues to perform well – Kelo-cote in particular enjoyed a very strong first half. We were pleased with the first half performance from Amberen, and the integration of the brand into our US-based operations is now complete.”
He continued: ”We expect the Group’s strong performance will continue throughout the second half and anticipate this will have a positive impact on cash generation and our ability to further deleverage by the year end.”